Tyrosine Kinase inhibitors (TKIs): Uses Side Effects For example, one group of tyrosine kinase inhibitors targets cancers such as non-small lung cancer, breast, colorectal and pancreatic cancer Those treatment side effects may range from mild skin rashes to life-threatening skin issues like Steven-Johnson syndrome toxic epidermal necrosis
Study Details | NCT07343479 | Sacituzumab Tirumotecan Plus . . . The purpose of this study is to assess the efficacy and safety of sac-TMT combined with third-generation EGFR-TKI with without intracranial radiotherapy in subjects with EGFR-mutated NSCLC and brain metastasis who have failed prior EGFR-TKI treatment
Nuvation Bio Announces FDA Acceptance of Supplemental New . . . Nuvation Bio Inc (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced today that the U S Food and Drug Administration (FDA
Adding Local Ablative Therapy to First-Line EGFR TKI . . . To evaluate LAT integration with first-line EGFR TKI monotherapy, the researchers conducted quantitative meta-analyses of randomized and nonrandomized comparative studies “evaluating EGFR TKI with or without LAT integrated into first-line treatment, either upfront or as consolidative therapy,” they explained
Strategies Beyond 3rd EGFR‐TKI Acquired Resistance . . . This review systematically summarizes acquired resistance mechanisms to third-generation EGFR-TKI, detection methods, potential biomarkers, and corresponding therapeutic strategies, with a focus on CNS metastasis-related resistance mechanisms and treatment approaches 2 Research Advances in Third-Generation EGFR-TKI 2 1 Introduction to EGFR
Phase 1 2 clinical trial of JIN-A02, a 4th generation EGFR . . . Phase 1 2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR-mutated advanced metastatic non-small cell lung cancer If you have the appropriate software installed, you can download article citation data to the citation manager of your choice Simply select your manager software from the list below and click Download
MUCIN 1 confers inflammatory memory of tyrosine kinase . . . Resistance of NSCLCs to osimertinib, an EGFR tyrosine kinase inhibitor (TKI), is mediated by pleotropic mechanisms that pose a significant challenge for subsequent treatment We report that the